share_log

Barrington Research Maintains Outperform on Anika Therapeutics, Raises Price Target to $37

Moomoo 24/7 ·  Mar 14 10:15

Barrington Research analyst Michael Petusky maintains Anika Therapeutics (NASDAQ:ANIK) with a Outperform and raises the price target from $29 to $37.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment